Showing results (21-30 of 564) with videos related to
Sort By:
Pageof 57
BMC Medicine|July 22, 2017
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?Robert Kemp, Vinay PrasadMayo Clinic Proceedings|May 30, 2016
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology DrugsChul Kim, Vinay PrasadSeminars in Oncology|September 20, 2017
Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeableVinay Prasad, Victoria KaestnerTrends in Cancer|January 12, 2021
N of 1 Data Sharing: The Impact of Data Sharing within the Hematology-Oncology Drug Products Division of the US FDAJennifer Gill, Vinay PrasadCardiovascular Diagnosis and Therapy|January 9, 2014
The reversal of cardiology practices: interventions that were tried in vainVinay Prasad, Adam CifuBMC Medicine|November 9, 2022
Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatmentTimothée Olivier, Vinay PrasadMonash Bioethics Review|March 8, 2024
COVID-19 vaccines: history of the pandemic's great scientific success and flawed policy implementationVinay Prasad, Alyson HaslamTranslational Oncology|April 15, 2024
Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trialTimothée Olivier, Vinay PrasadContemporary Clinical Trials|December 25, 2013
The misguided ethics of crossover trialsVinay Prasad, Christine GradyJAMA Internal Medicine|September 12, 2017
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalVinay Prasad, Sham MailankodyPageof 57